Sickle Cell Disease Treatment Market Size and Forecast 2024-2033|Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG

Overview and Scope

Sickle cell disease (SCD), also known as sickle cell anemia, is a genetic disorder affecting hemoglobin, a protein in red blood cells. A mutation in the hemoglobin gene causes the production of defective hemoglobin, referred to as hemoglobin S (HbS), in people with sickle cell disease. The sickle cell disease treatment removes blockages, enhances blood flow and repairs damaged tissues.

Sizing and Forecast

The sickle cell disease treatment market size has grown rapidly in recent years. It will grow from $2.46 billion in 2023 to $2.95 billion in 2024 at a compound annual growth rate (CAGR) of 20.0%. The growth in the historic period can be attributed to disease understanding, blood transfusions, pain management, hydroxyurea therapy.

The sickle cell disease treatment market size is expected to see rapid growth in the next few years. It will grow to $5.75 billion in 2028 at a compoundannual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to gene editing and gene therapy, new drug development, telemedicine and remote monitoring, global health initiatives. Major trends in the forecast period include curative therapies, pain management alternatives, global collaborations, patient advocacy and engagement.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report

Segmentation & Regional Insights

The sickle cell disease treatment market covered in this report is segmented –

1) By Treatment Modality: Blood Transfusion; Pharmacotherapy; Bone Marrow Transplant

2) By Disease Type: Sickle Cell Anemia; Hemoglobin Sickle C Disease (HbSC); Other Disease Types

3) By Route Of Administration: Oral; Parenteral

4) By End-User: Hospitals; Specialty Clinics; Other End-Users

North America was the largest region in the sickle cell disease treatment market in 2023. The regions covered in sickle cell disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13048&type=smp

Major Driver Impacting Market Growth

The increasing demand for blood transfusions is expected to propel the growth of the sickle cell disease treatment market going forward. A blood transfusion is a medical procedure in which blood or blood products are given from one person (the donor) to another (the receiver). Blood transfusions are a crucial part of treatment for sickle cell disease (SCD) patients because they improve blood’s ability to carry oxygen and lessen the difficulties associated with vaso-occlusion. For instance, in December 2022, according to gov.UK, a UK-based public sector information platform, in 2021, the number of blood donations increased, with 1.7 million donations made around the UK. Further, in January 2022, according to Mid-Atlantic Long-Term Care, a US-based provider of specialized 24-hour triage on-call service, in the US, around 29,000 units of red blood cells, 5,000 units of platelets and 6.500 units of plasma are needed every day. Therefore, the increasing demand for blood transfusions is driving the growth of the sickle cell disease treatment market.

Key Industry Players

Major players in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Silver Lake Research Corporation0.45, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Arena Pharmaceuticals Inc., Mast Therapeutics Inc.

The sickle cell disease treatment market report table of contents includes:

1. Executive Summary

2. Sickle Cell Disease Treatment Market Characteristics

3. Sickle Cell Disease Treatment Market Trends And Strategies

4. Sickle Cell Disease Treatment Market – Macro Economic Scenario

5. Global Sickle Cell Disease Treatment Market Size and Growth

26. South America Sickle Cell Disease Treatment Market

27. Brazil Sickle Cell Disease Treatment Market

28. Middle East Sickle Cell Disease Treatment Market

29. Africa Sickle Cell Disease Treatment Market

30. Sickle Cell Disease Treatment Market Competitive Landscape And Company Profiles

Top Major Players: